IRF-4 Lentiviral Activation Particles (m): sc-421148-LAC

Mouse Irf4 encodes interferon regulatory factor 4 (IRF-4), a transcription factor that integrates antigen receptor and cytokine cues to shape lymphocyte differentiation and effector programs. IRF-4 coordinates gene expression networks involved in B cell class-switch recombination and plasma cell development, as well as CD4+ T cell lineage specification and CD8+ T cell responses, acting in concert with partners such as BATF/JUN and NF-κB. It is embedded within pathways controlling immune activation, metabolic reprogramming, and chromatin accessibility in hematopoietic cells. Dysregulated IRF-4 activity has been linked to altered immune homeostasis and inflammation-associated phenotypes, supporting its use in mechanistic studies of immune signaling and transcriptional circuitry.

IRF-4 Lentiviral Activation Particles (m) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient Irf4 upregulation across a broader range of human cell types.

IRF-4 Lentiviral Activation Particles (m) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the Irf4 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous IRF-4 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native Irf4 genomic locus and regulatory architecture.

The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.